Results From REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2019年 / 17卷 / 03期
关键词：
ACUTE GVHD;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3 / 5
页数：3
相关论文
共 50 条
  • [1] Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease
    Jagasia, Madan
    Perales, Miguel-Angel
    Schroeder, Mark A.
    Ali, Haris
    Shah, Nirav N.
    Chen, Yi-Bin
    Arbushites, Michael C.
    Dawkins, Fitzroy
    Tian, Chuan
    Khoury, Hanna Jean
    BLOOD, 2018, 132
  • [2] Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease: Results from the Phase 2 REACH1 Trial
    Jagasia, Madan
    Ali, Haris
    Schroeder, Mark A.
    Shah, Nirav N.
    Chen, Yi-Bin
    Dawkins, Fitzroy
    Arbushites, Michael
    Tian, Chuan
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [3] Ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute Graft-vs-host disease: 6-month follow-up data from the phase 2 REACH1 trial
    Jagasia, Madan
    Ali, Haris
    Schroeder, Mark A.
    Shah, Nirav N.
    Chen, Yi-Bin
    Dawkins, Fitzroy
    Arbushites, Michael
    Tian, Chuan
    Perales, Miguel-Angel
    BONE MARROW TRANSPLANTATION, 2019, 54 : 79 - 80
  • [4] Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
    Teshima, Takanori
    Onishi, Yasushi
    Kato, Koji
    Taniguchi, Shuichi
    Miyamura, Koichi
    Fukushima, Kentaro
    Kato, Jun
    Ishikawa, Takayuki
    Doki, Noriko
    Nakamae, Hirohisa
    Maeda, Yoshinobu
    Inamoto, Yoshihiro
    Okada, Masaya
    Maki, Akio
    Shimada, Fumika
    Tajima, Takeshi
    Wroclawska, Monika
    Zeiser, Robert
    Onizuka, Makoto
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (01) : 106 - 116
  • [5] Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
    Jagasia, Madan
    Perales, Miguel-Angel
    Schroeder, Mark A.
    Ali, Haris
    Shah, Nirav N.
    Chen, Yi-Bin
    Fazal, Salman
    Dawkins, Fitzroy W.
    Arbushites, Michael C.
    Tian, Chuan
    Connelly-Smith, Laura
    Howell, Michael D.
    Khoury, H. Jean
    BLOOD, 2020, 135 (20) : 1739 - 1749
  • [6] Angiogenic factors and inflammation in steroid-refractory acute graft-vs-host disease
    Holtan, Shernan G.
    Arora, Mukta
    TRANSLATIONAL RESEARCH, 2016, 167 (01) : 80 - 87
  • [7] Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-vs-Host Disease-Another Hopeful Step Forward
    Alvarnas, Joseph Clemente
    JAMA NETWORK OPEN, 2021, 4 (01)
  • [8] Biomarker and Safety Analyses of Patients With Steroid-Refractory Acute Graft-Vs-Host Disease Treated With Ruxolitinib or Best Available Therapy in the Randomized, Phase 3 REACH2 Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 10 - 12
  • [9] Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease in Expanded Access Programs
    Schroeder, Mark A.
    Toama, Wael
    Fiala, Mark A.
    Naim, Ahmad
    Blithe, Amy
    Paranagama, Dilan
    DiPersio, John F.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [10] Ruxolitinib vs Best Available Therapy in Patients With Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease: Primary Findings From the Phase 3, Randomized REACH3 Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 6 - 8
12345